1235 GMT - Roche Holding shares trade at a premium to those of peers, which will be difficult to justify if the launches of its next drugs don't deliver on expectations, Jefferies analysts say in a research note. There were no big surprises in the Swiss drugmaker's update on its pharma business held Monday and 2027 is shaping up to be a year more focused on regulatory filings than on clinical-trial results, the analysts say. "What is now perhaps even clearer is that 2027 giredestrant and fenebrutinib launches must deliver, if approved, as key clinical catalysts don't emerge until closer to 2028," Jefferies says, referring to Roche's new drugs for breast cancer and multiple sclerosis, respectively. Shares fall 1.2%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments